The present analyses were based on 59 out of the 63 patients, receiving at least 80% of the scheduled drug dose in the first treatment course, in order to assess the biological effect of IL-2 with and without histamine in relation to baseline and on-treatment blood samples and tumour-tissue biopsies. Here, IL2 is linked to neoplasm.